ALEXANDRA GLENN: Open Payments
NPI 1275094088 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,234 in 195 payments from 48 companies in 2025. Trend: 2023 $2,246 · 2024 $3,373 · 2025 $4,234
Food & beverage: $4,039Education: $195
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 21 | $553 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $281 |
| Incyte Corporation | 9 | $271 |
| PFIZER INC. | 13 | $269 |
| Novartis Pharmaceuticals Corporation | 11 | $217 |
| GlaxoSmithKline, LLC. | 11 | $177 |
| Celgene Corporation | 9 | $164 |
| Blueprint Medicines Corporation | 4 | $129 |
| SERVIER PHARMACEUTICALS LLC | 6 | $123 |
| Alexion Pharmaceuticals, Inc. | 6 | $123 |
Products named: RYBREVANT, REBLOZYL, TALVEY, AYVAKIT, FRUZAQLA, ULTOMIRIS, NINLARO, OJJAARA.
Industry payments across AL — which companies pay providers there.
